Key result
Implantation of the Myval Octacor valve reduced median right ventricular systolic pressure from 68.5 to 33 mmHg and peak gradient from 30 to 6.5 mmHg, with no reported device complications.
Why the study?
Transcatheter pulmonary valve implantation is preferred for dysfunctional right ventricular outflow tracts, but limited reports exist regarding the new Myval Octacor valve in the pulmonary position.
Does transcatheter pulmonary valve implantation using the Myval Octacor valve improve haemodynamics and provide safety in patients with dysfunctional right ventricular outflow tract conduits and pulmonary valve bioprostheses?
Observational (n=10)
No
Does transcatheter pulmonary valve implantation using the Myval Octacor valve improve haemodynamics and provide safety in patients with dysfunctional right ventricular outflow tract conduits and pulmonary valve bioprostheses?
The Myval Octacor valve demonstrates safety and immediate haemodynamic improvement for transcatheter pulmonary valve implantation in dysfunctional right ventricular outflow tracts.
Initial cohort supports short-term feasibility of Myval Octacor in pulmonary position; extends limited reports but leaves open durability and comparative efficacy.
BACKGROUND: Transcatheter pulmonary valve implantation has emerged as a minimally invasive and preferred therapeutic option for patients with dysfunction of previously repaired right ventricular outflow tracts. The Myval™ Octacor valve is a new device designed for this purpose, though limited reports exist regarding its use in the pulmonary position. AIMS: To report the immediate and short-term outcomes of percutaneous pulmonary valve implantation using the Myval™ Octacor valve in patients with severe right ventricular-pulmonary artery conduit or pulmonary valve bioprosthesis dysfunction. METHODS: This was a single-centre retrospective review of data obtained from case files. RESULTS: The Myval™ Octacor valve was used in ten patients with a mean age of 34.5 ± 7.4 years. The median procedure duration and fluoroscopy time were 146 minutes and 30.5 minutes, respectively. The median Z-score for valves used was -0.5. The median right ventricular systolic pressure decreased from 68.5 mmHg pre-procedure to 33 mmHg post-procedure. The median peak instantaneous gradient across the right ventricular outflow tract or conduit decreased from 30 mmHg to 6.5 mmHg. There were no reported incidences of frame fracture, conduit rupture, device embolisation, or endocarditis. CONCLUSION: This is the first UK experience of using the new-generation Myval™ Octacor valve in percutaneous pulmonary valve implantation. The results demonstrate the valve's safety and clinical efficacy, with favourable outcomes in terms of procedural success, haemodynamic improvement, and echocardiographic findings.
No takes yet. Share an insight, caveat, or question.
Badawy et al. (2025) conducted an observational in Severe right ventricular-pulmonary artery conduit or pulmonary valve bioprosthesis dysfunction (n=10). Myval™ Octacor valve was evaluated on Immediate and short-term outcomes including haemodynamic improvement and procedural success. Implantation of the Myval Octacor valve reduced median right ventricular systolic pressure from 68.5 to 33 mmHg and peak gradient from 30 to 6.5 mmHg, with no reported device complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: